Background:
Stenotrophomonas maltophilia is a multi-drug resistant, gram-negative bacterium that causes opportunistic infections and is associated with high morbidity and mortality in severely immunocompromised individuals.
Aim:
To find out the drug target and a novel inhibitor for Stenotrophomonas maltophilia.
Objectives:
Current study focused on the identification of specific drug target by subtractive genomes analysis and to find
out the novel inhibitor for the identified target protein by virtual screening, molecular docking, and molecular simulation
approach.
Materials and Methods:
In this study, we performed a subtractive genomics approach to identify the novel drug target for
S.maltophilia. After obtaining the specific target, the next footstep was to identify inhibitors that include the calculation of
2D Similarity search, Molecular Docking, and Molecular Simulation for the drug development for the S.maltophilia.
Results:
With an efficient subtractive genomic approach, five unique targets as the impressive therapeutics founded out of
4386 protein genes. In which UDP-D-acetylmuramic (murF) was the most remarkable target. Further virtual screening,
docking, and dynamics resulted in the identification of seven novel inhibitors.
Conclusion:
Further, in vitro and in vivo bioassay of the identified novel inhibitors could facilitate effective drug use against
S.maltophilia.
Potential therapeutic drug target identification in Community Acquired-Methicillin Resistant Staphylococcus aureus (CA-MRSA) using computational analysis
